TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04064060: A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Sponsor: Celgene · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 665 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,886,576

Rescue Site Savings

+$1,902,516

Unlock Full NCT04064060 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04064060 Rescue Dossier →